clinical trial · NCT06030076
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Almirall, S.A.·—·recruiting·n = 50
Plaque PsoriasisTildrakizumab
brief summary
The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the individual rationales for switching biologics.
started
Sep 6, 2023
primary completion
Oct 1, 2025
completion
Oct 1, 2025
last updated
Jan 29, 2025
official title
A Non-interventional, Prospective Cohort, Multicentre, Real-world Evidence Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis in Austria and Switzerland
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol